International registry of congenital porto-systemic shunts: a multi-centre, retrospective and prospective registry of neonates, children and adults with congenital porto-systemic shunts

Simona Korff1*, Khaled Mostaguir2, Maurice Beghetti3, Lorenzo D'Antiga4, Dominique Debray5,6, Stéphanie Franchi-Abella5,7, Emmanuel Gonzales8, Florent Guerin5,9, Anne-Lise Hachulla10, Virginie Lambert11,12, Periklis Makrythanasis13,14,15, Nicolas Roduit16, Laurent Savale17,18,19, Marie-Victoire Senat20, Joël Spaltenstein21, Frank van Steenbeek22, Barbara E. Wildhaber1, Marcel Zwahlen23 and Valérie A. McLin1,5

Abstract

Background: Congenital portosystemic shunts (CPSS) are rare vascular malformations associated with the risk of life-threatening systemic conditions, which remain underdiagnosed and often are identified after considerable diagnostic delay. CPSS are characterized by multiple signs and symptoms, often masquerading as other conditions, progressing over time if the shunt remains patent. Which patients will benefit from shunt closure remains to be clarified, as does the timing and method of closure. In addition, the etiology and pathophysiology of CPSS are both unknowns. This rare disorder needs the strength of numbers to answer these questions, which is the purpose of the international registry of CPSS (IRCPSS).

Method: A retrospective and prospective registry was designed using securiTrial® by the ISO certified Clinical Research Unit. Given that a significant number of cases entered in the registry are retrospective, participants have the opportunity to use a semi-structured minimal or complete data set to facilitate data entry. In addition, the design allows subjects to be entered into the IRCPSS according to clinically relevant events. Emphasis is on longitudinal follow-up of signs and symptoms, which is paramount to garner clinically relevant information to eventually orient patient management. The IRCPSS includes also three specific forms to capture essential radiological, surgical, and cardiopulmonary data as many times as relevant, which are completed by the specialists themselves. Finally, connecting the clinical data registry with a safe image repository, using state-of-the-art pseudonymization software, was another major focus of development. Data quality and stewardship is ensured by a steering committee. All centers participating in the IRCPSS have signed a memorandum of understanding and obtained their own ethical approval.

*Correspondence: simona.korff@hcuge.ch

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusion: Through state-of-the-art management of data and imaging, we have developed a practical, user-friendly, international registry to study CPSS in neonates, children, and adults. Via this multicenter and international effort, we will be ready to answer meaningful and urgent questions regarding the management of patients with CPSS, a condition often ridden with significant diagnostic delay contributing to a severe clinical course.

Keywords: Congenital, Portosystemic, Shunt, Registry, Liver, Rare disease

Background

Congenital portosystemic shunts (CPSS) are a rare malformation in humans accepted to result from incomplete vascular remodeling during embryogenesis, whereby the blood leaving the intestine does not pass entirely through the liver via the portal vein. Instead, it bypasses the liver partially or completely through an anatomically aberrant vessel connecting the porto-mesenteric system to the systemic venous circulation. CPSS are broadly divided into two categories: intrahepatic (IH) and extrahepatic (EH). The significance of this distinction is two-fold. First, they are anatomically different and therefore the relative proportion of portosystemic bypass differs between forms, with EH shunts often associated with a much more significant amount of splanchnic blood derivation than IH. Second, IH seem to be more likely to close spontaneously early in life [1, 2].

The systemic repercussions of abnormal portosystemic shunting and decreased hepatic portal flow are numerous and potentially serious. They include signs and symptoms such as hepatic encephalopathy, pulmonary vascular diseases (hepatopulmonary syndrome or pulmonary arterial hypertension), benign or malignant liver tumors, and biological and metabolic disorders [3–6]. Other less well-described associations include in utero growth retardation or tall stature in infancy, nephropathy, thyroid dysfunction, and coagulation abnormalities. In adults, CPSS have been reported at all ages, often as incidental findings, although in referral centers they are now sought as part of the work up of pulmonary hypertension [7].

The true incidence of CPSS is unknown, but it is estimated to affect 1/30–50,000 live births [4, 8]. CPSS is also known to be associated with other malformations or syndromes, such as congenital heart disease, heterotaxy, polysplenia syndrome, chromosomal anomalies, cutaneous or hepatic hemangiomas [3, 4, 9]. CPSS can be diagnosed at any age, either because the patient is symptomatic or as an incidental finding. Given their rarity, patients presenting with symptoms of systemic complications may experience significant diagnostic delay, because many of CPSS signs and symptoms mimic other conditions. Spontaneous closure of the CPSS has been reported to occur in some anatomic forms during the first one to two years of life [1, 2]. When the CPSS remains patent, radiologic or surgical closure of the CPSS may prevent, resolve, or stabilize complications [5, 6, 9, 10]. Yet, the conspicuous gap to fill in our current knowledge is which patient will benefit from shunt closure and when.

A preliminary analysis of 246 patients included 122 IH, 120 EH, and 3 patients with both IH and EH followed in centers participating in the IRCPSS [1, 2]. Among patients diagnosed pre-natally, a majority had IH shunts (75%), 189 (76%) patients were diagnosed post-natally at a mean age of 39.1 mo (0–200) for IH and 61.9 mo (0–192) for EH. IH and EH shunts were equally frequent when diagnosed after birth. IH shunts were more often an incidental finding. 24% of all CPSS were identified pre-natally. Among patients diagnosed post-natally, symptoms were equally frequent among patients with IH (57%) or EH (61%) CPSS. In addition, patients with EH CPSS were more likely to have several symptoms than patients with IH CPSS. They were also more likely to have liver nodules on imaging (40.7% vs. 26%). Closure: 184 children with CPSS were closed including 11 patients with 2 steps closure. Among these 184 patients 54% of IH CPSS and 5% of EH CPSS closed spontaneously. 46% of IH CPSS required medical or surgical closure of which nearly 40% for a preventive indication. 94% of patients with EH CPSS were closed through a procedure, of which 41% were preventive. Based on these preliminary data, it can be stated that IH and EH shunts were equally frequent in this multicenter retrospective cohort of CPSS in children. CPSS are a cause of severe symptoms in children and should be sought in infants with hypoglycemia or cholestasis. In older children, they should be considered in the differential diagnosis of liver nodules, cardiopulmonary symptoms or neurocognitive deficits. Given the potential severity of complications, preventative closure should be considered, although timing and approach need further study, something which the IRCPSS aims to address. While this preliminary analysis has offered some insight into the diagnosis and management of CPSS, much is unknown regarding both etiology and management, which is the basis for the registry presented herein.

Therefore, the main aim of the International Registry of Congenital Porto-Systemic Shunts (IRCPSS) is to characterize the clinical course of patients with CPSS and to identify subjects at risk of developing systemic complications with the overarching goal to stratify risks and standardize care of patients with CPSS. Although CPSS
are increasingly suspected and sought in specialized centers, much is still unknown clinically, histologically, and biologically.

**Methods**

**Study design**

Given the rarity of CPSS, it is crucial to emphasize the importance of recording both prevalent and incident cases and to include as many centers as possible. It is for these reasons that the registry is designed as both a retrospective and prospective cohort study. At the time of print, it is estimated that >500 retrospective cases are currently followed by centers participating in the IRCPSS. Although medical records may be incomplete, we aim to include all cases in the registry given the rarity of the condition and the importance of garnering sufficient numbers to improve the understanding of the full spectrum of these rare malformations.

**Descriptive data**

The following parameters are essential to improve our understanding of the medical course of patients with CPSS: medical history, anatomical characteristics of the CPSS, radiological progression of the CPSS over time, and the longitudinal follow up of signs and symptoms over time. Therefore the registry is designed to include clinical, imaging, histological, and biological data collected from the day of diagnosis until five years after CPSS closure (spontaneous or procedural), or any clinically relevant visit thereafter. As this is not an interventional trial, each participating center sets its own clinical follow-up schedule and enters into the registry what the site principal investigator (PI) deems to be clinically relevant visits.

**Imaging**

Imaging is crucial to diagnose and characterize CPSS, and to develop a clear and consensual nomenclature. Images are collected in all collaborating centers and stored in a dedicated imaging server meeting all current security norms. Scanned histology slides can be uploaded to the same server. Images are linked to the clinical registry using a secure process described below (image management).

**Study population**

Since the registry aims to understand the full spectrum of CPSS, the IRCPSS includes neonates, children, and adults and follows subjects longitudinally. Any neonate, child or adult with CPSS is eligible for inclusion. Patients diagnosed in utero are enrolled at birth. Patients with chronic liver disease and secondary shunts are excluded.

---

**Table 1** List of parameters recorded in the IRCPSS

| Longitudinal data                          |  |
|--------------------------------------------|--|
| Signs and symptoms                        |  |
| Clinical exam                              |  |
| Imaging                                    |  |
| Laboratory                                 |  |
| Cardio-pulmonary complications             |  |
| Adverse events and complications related to closure |  |

| Crosssectional data                       |  |
|-------------------------------------------|--|
| Inclusion criteria                        |  |
| Demographics                              |  |
| Medical history                           |  |
| Pre-natal history                         |  |
| Mode of presentation                      |  |
| Associated malformations (pre- and post-natal) |  |
| Shunt classification (pre- and post-natal) |  |
| Indication for closure                    |  |
| Type of closure and procedure             |  |
| Available tissue samples and genetic workup |   |
| Termination of follow up                  |  |

**Model conception**

Understanding the clinical question is central to developing the optimal registry. In the case of CPSS the crux of managing patients is to determine who will develop systemic complications, who will close spontaneously, and consequently who will need shunt closure, and when. While the preliminary analysis described above helps guide which patients warrant a closer follow-up, it is still unclear which patients may (not) need surgical or radiological closure, both procedures being laden with risks of significant complications, something which the registry aims to capture. Furthermore, it remains to be determined, among those patients who will develop associated signs or symptoms, which of these will regress following shunt closure, and which will need further specialized treatment. Therefore, the IRCPSS needs to capture longitudinal information in order to offer investigators the opportunity to analyze these very specific questions in nested studies.

There are several other challenging aspects of managing patients with CPSS which the registry aims to tackle. Among them, some of the primordial questions include how to proceed with complex shunts, how to follow up shunts diagnosed in utero, and the complexity of managing CPSS in the setting of congenital heart disease. The main clinical questions and goals of the IRCPSS determined the parameters (Table 1) as well as the structure of the registry (Table 2).
Clinical data collection
Only available data collected as part of routine clinical care of each center are recorded in the registry; additional medical visits or lab draws are not necessary for participation. Informed consent is obtained from participants or legal representatives in the case of pediatric subjects according to the ethical legislation of the country.

There are two semi-structured data sets. A Minimal Data Set (MDS) is available to include and to facilitate data entry for historical cases whose files are often very incomplete. The MDS does not include pre-natal data, medical history, pre-closure visits, or surgical or radiological information at closure. In turn, the Complete Data Set (CDS) is designed for prospective data and complete retrospective data. It includes pre-natal data and data listed in Table 1.

Data collected at each visit include demographic data (age, sex, weight, and height), clinical exams, and laboratories. Information on the type of imaging performed is also captured (angiography, magnetic resonance imaging, scintigraphy, ultrasound, computed tomography, electrocardiogram). Signs and symptoms are tracked at each visit in order to follow their course longitudinally before and after shunt closure (Fig. 1). For quantifiable data, such as liver nodules, it is possible to follow number and size over time.

Additionally, some data are collected at specific time-points during follow-up. At the first visit—also called “Basic Data & Early Diagnosis visit”—the following are recorded: patient medical history, shunt mode of presentation, and anatomical classification according to imaging [11]. In the registry each complex shunt is identified and has its own classification to facilitate follow-up through multiple closures. If a new shunt is identified, it can be managed independently from the first one. Associated malformations and prenatal data are also recorded by the system when available. Specific surgical and radiological data are collected during the closure visit. Cardio-pulmonary complications are documented and followed in a specific and independent cardio-pulmonary form which can be collected/recorded at any time-point. There are three [3] specific forms to be completed independently by specialists: cardiopulmonary, surgery, interventional radiology (Fig. 1). Given that clinically relevant cardiopulmonary visits may be required at different time points than shunt-specific visits, these can be entered independently. If the clinical course of the patient is favorable, follow up in the registry is terminated at five years after the last closure or at the last visit if the follow-up of the subject is shorter. A more detailed structure of the registry in UML presentation is available as Additional file 1.

Data management and collection
Data management is performed by the Clinical Research Center at Geneva University Hospitals and Faculty of Medicine. The unit is certified ISO 9001/2008, and guarantees full compliance with Good Clinical Practices (GCP). Physical and electronic access to the data center is logged and limited to authorized personnel. Vulnerability testing is performed regularly to reduce potential exposure. The internal network is protected by multiple firewalls, proxy, reverse-proxy and state-of-the-art anti-virus solutions. Data are managed and physically stored using secuTrial® [12], a professional, specialized, browser-based, and GCP-compliant system.

Table 2 Parameters recorded in the IRCPSS related to main clinical questions and goals

| Clinical questions and goals | Cross-sectional data | Longitudinal data |
|-----------------------------|----------------------|-------------------|
| Clear and consensual nomenclature | Shunt classification linked to images | Cardio-pulmonary complications |
| Correlation of prenatal findings with post-natal anatomy | Patient medical history, mode of presentation, associated malformations, shunt classification | Signs and symptoms before closure |
| Type of cardiopulmonary complication and prognosis | Mode of presentation | Signs and symptoms before and after closure |
| Who will develop associated signs or symptoms? | Pre-natal history, pas medical history, associated malformations, mode of presentation, shunt classification | Signs and symptoms, clinical exams, imaging, laboratory, adverse events and complications |
| Which signs or symptoms regress after shunt closure and which will need further specialized treatment? | Associated malformations, shunt classification, mode of presentation, indication for closure, type of closure and procedure |
| Closure, who and when? Surgical or radiological closure? | Signs and symptoms, clinical exams, imaging, laboratory, adverse events and complications |
| How to proceed with complex shunts? | Associated malformations, shunt classification, mode of presentation, indication for closure, type of closure and procedure | Shunt identification, signs and symptoms, clinical exams, imaging, laboratory, adverse events and complications |
for collecting, validating, and visualizing patient data in clinical research trials and registries. secuTrial® was adapted specifically to the complex needs of the registry. Data collected for each research subject constitute the subject’s electronic Case Report Form (eCRF). Each eCRF includes the parameters and follows the structure previously described under “Clinical Data Collection”. Research subjects are automatically pseudonymized and access to their data is strictly limited to authorized users. No personal data or data that may easily identify subjects are recorded, also for imaging. Each participating center has its own dedicated and protected area. The forms containing the data are edited and accessed by the study personnel based on a pre-defined set of roles and authorizations. All system logins, interventions, data modifications, and form status changes are thoroughly recorded for audit purposes.

**Data quality**

The implementation of the data model was designed to avoid redundancy, to facilitate data capture, while minimizing logic and typing errors (e.g., automatic conversion of laboratory values, assessment of newly entered values with regard to previously entered ones, etc.). In addition to the automatic quality rules, data validation and review is thoroughly ensured by members of the registry steering committee (SC). To facilitate data and activity monitoring, up-to-date graphical and text reports, as well as descriptive statistics, are available in real time (Fig. 2a). Data management is further strengthened by an interactive, electronic process to comment, query and claim corrections, thereby ensuring high data quality.

**Navigability**

The built-in graphical interface has been optimized to facilitate navigability as much as possible during the data capture and data validation processes (Fig. 2b). Color codes indicate completion, validation, and accuracy status of the different data sections facilitating navigation between different visits and clinical categories (or subdomains) by investigators.

**Image management**

In addition to clinical data, the project includes DICOM imaging data that has been de-identified using the KARNAK [13] gateway. All personally identifying information (PII) is removed from non-pixeldata DICOM attributes. In cases such as ultrasound imaging, where PII is often burnt-in to the pixeldata, the images are modified to remove the identifying information. Image management is performed within a dedicated image server built on the KHEOPS platform [14]. The KHEOPS platform provides specific access controls based on users’ needs and an organizational structure, such as images submitted by different recruitment centers, remain isolated from each other. The image server is hosted in the data center of the Campus Biotech in Geneva under the responsibility of the Institute of Translational Molecular Imaging. This institute is affiliated with the University of Geneva and the Swiss Federal Institute of Technology. Within secuTrial®, each patient eCRF includes a redirection link that
ensures a dynamic connection between the clinical registry and the image server.

**Data analysis**

The planned statistical analyses are partly of a descriptive and partly of a comparative nature. Examples of descriptive analyses include describing the prevalence and incidence of a particular extrahepatic complication related to CPSS; for example pulmonary hypertension, liver nodules or tall stature. Each sign or symptom can in turn be studied by describing associations with neonatal findings or analyzing severity, treatment, and outcomes. Comparative analyses will compare demographic or clinical characteristics between patients with or without

---

**Fig. 2**

a secuTrial®, overview of the data entry progress and completion available in real time for each center.  
b secuTrial®, overview of subject visit plan and forms.
a given sign or symptom: for example looking for differences between patients who develop pulmonary hypertension and those who do not. Among those who do, functional characteristics (for example New York Heart Association functional class) will be compared and regression models developed with the aim to identify associations.

**Description of recruiting centers**
The first step for a new center to be part of the IRCPSS is to obtain the approval of its ethics committee. Consent forms are available in English, French, German, and Italian. If needed a Data Transfer Agreement (DTA) model has also been established by the legal department of University Hospitals Geneva to govern the transfer, use, and protection of data.

Given the complexity of CPSS management, it is expected that each collaborating center include a hepatologist, surgeon, radiologist, cardiologist, and pulmonologist on their CPSS team to enroll patients in the registry. The highly specialized nature of the data is beyond the expertise of most research coordinators, and therefore specialists have to enter highly specialized data. The site PI of each center acts as a coordinator among specialties adapting to the configuration and availability of local resources. Regardless, it is expected that cardiologists enter their data, given the complexity of the specific reports. For data quality issues, each specialist validates the data for his particular sub-specialty in his center, and a second level of validation is performed by the SC.

The prototypic participating center is a recognized, national and international center for liver disease with expertise in CPSS diagnosis and management in children or adults. At the time of print, 56 centers in 23 countries are part of the registry, 17 of which have obtained the approval of their ethics committee and 11 have initiated data entry.

**Data stewardship and publications**
All centers participating in the IRCPSS have access to their own data and may agree to share their data with another center under the auspices of an ancillary project validated by the SC. Members of the SC have access to all data for oversight and quality control. Publication policy is defined by the SC in a Memorandum of Understanding signed by all centers entering data in the registry. Authorship is determined according to the scientific contribution of an individual to a given project or manuscript, and patient enrollment is acknowledged by listing all site contributors in alphabetical order in the ‘contributors’ section as found in PubMed. Partners wishing to conduct a nested study may submit to the SC a short study proposal for review and approval by the SC (contact via www ircpss com).

**Discussion and conclusion**
The purpose of the IRCPSS registry is to bring together a vast collection of longitudinal, clinical, and imaging data across several systems in order to characterize the clinical course of patients with CPSS in detail with a view to harmonize clinical decision making and improve patient management. The challenge has been to build a solid and suitable data model encompassing the various clinical sub-domains and their complexity, while remaining as flexible as possible to facilitate data capture, ease of use, and long-term adaptability. We believe that we have successfully designed a tool that also offers the required flexibility to capture data across the many participating centers. It also offers the possibility for future technical evolution, including towards the development of interventional studies.

CPSS are a rare condition, and previous single-center studies have not been powered enough to answer some of the key questions that this large multicenter registry will be able to tackle. One of the unique features of this registry is that it brings together longitudinal data about the CPSS itself, with that of several organ systems in order to uniquely follow the course of systemic signs and symptoms over time. Furthermore, the creation of the IRCPSS has garnered the interest of multiple centers across continents. Importantly, it has succeeded in securing the commitment of multidisciplinary teams in all these centers. This is essential for developing a detailed understanding of CPSS and stems from the existent reality of clinical practice in the respective centers. In most instances, patients with CPSS cannot be managed in isolation, but rather need the collective know-how of multidisciplinary teams comprised of interventional radiologists, hepatologists, surgeons, endocrine specialists, pulmonologists and cardiologists, an aspect which this registry also aims to favor.

Finally, CPSS are complex vascular malformations with potentially severe systemic consequences often masquerading as other common complaints. Increasing awareness is therefore paramount and the creation of the IRCPSS enhance the visibility of this rare vascular malformation.

**Abbreviations**
CPSS: Congenital portosystemic shunts; IRCPSS: International Registry of Congenital PortoSystemic Shunts; IH: Intrahepatic; EH: Extrahepatic; MDS: Minimal Data Set; CDS: Complete Data Set; GCP: Good Clinical Practices; eCRF: Electronic Case Report Form; SC: Steering committee; ITMI: Institute of Translational Molecular Imaging; EPFL: Swiss Federal Institute of Technology; DTA: Data Transfer Agreement; PI: Principal Investigator.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02412-8.

Additional file 1. Supplementary Figure. UML presentation: package/class & use case diagram - relationships: 0.1 no instance or 1 instance, 0,* zero or more instance, 1,* at least one instance Purple: visits over time Yellow: clinical forms and imaging Green: specific forms at the Basic Data & Diagnosis visit Red: specific forms at closure Grey: Specific forms at any time-point.

Acknowledgements

The authors thank Liliana Bolliger of the Institute of Social and Preventive Medicine (ISPM) for her guidance during the registry conception, Antoine Poncet of the clinical epidemiology service of the University Hospitals Geneva for his statistical advice, the numerous clinicians who contributed to eCRF conception, and to the numerous families who have consented to contribute to bettering our understanding of CPSS.

Author contributions

SK, KM, MB, DD, SFA, EG, FG, VL, LS, BW and VM conceptualized and designed the registry. They are actively involved in the implementation of the registry at their institutions. SK, KM and VM wrote the manuscript. All authors read and approved the final manuscript.

Funding

The IRCPSS is funded by a network grant from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition and by a Registry Grant from the European Association for the Study of the Liver. It has garnered support from the Ferrari Foundation and the Prém'Enfance Fondation in Geneva, Switzerland, and benefits from operational support from the University Hospitals Geneva, and The University of Geneva. Collaborators include the European Reference Network RARE-LIVER, the Vascular Liver Disease Group (VALDIG), Geneva, and The University of Geneva. Funding is also supported by the Ferrari Foundation and the Prim'Enfance Fondation in Geneva, Switzerland. The European Association for the Study of the Liver. It has garnered support from the European Reference Network RARE-LIVER, the Vascular Liver Disease Group (VALDIG), the Centre de Référence Maladies Vasculaires du Foie, and the Filière de Santé Maladies Rares du Foie de l'Adulte et de l'Enfant (FILFOIE).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Ethical approval of the sponsor was granted by the Geneva cantonal Research Ethics Commission (CCER) in Switzerland on the 26th of April 2018 (2018-00413). All other centers participating in the IRCPSS have obtained their own ethical approval and all subjects gave informed consent.

Consent for publication

Not applicable.

Competing interests

Lorenzo D’Antiga serves on the advisory board and/or consults for the following companies: Selecta, Vivet, Spark, Alexion, Mirum, Albireo. The other authors have not competing interests related to the content presented in this manuscript.

Author details

1Swiss Pediatric Liver Center, Department of Pediatrics, Gynecology, and Obstetrics, University Hospitals Geneva, University of Geneva, Geneva, Switzerland. 2Clinical Research Centre, Geneva University Hospitals, University of Geneva, Geneva, Switzerland. 3Congenital Heart Center, Division of Pediatric Subspecialties, Department of Pediatrics, Gynecology, and Obstetrics, University Hospitals Geneva, University of Geneva, Geneva, Switzerland. 4Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy. 5ERN RARE LIVER, Hamburg, Germany. 6Pediatric Liver Unit, Competence Center for Rare Vascular Diseases, Necker Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France. 7Pediatric Radiology Department, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France. 8Pediatric, Hepatology and Liver Transplantation, Reference Center for Liver Vascular Diseases, FSMR FILFOIE, Hépatino, Inserm U 1193, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France. 9Department of Paediatric Surgery, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France. 10Division of Radiology, University Hospitals Geneva, Geneva, Switzerland. 11Department of Paediatric Radiology, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France. 12Congenital Cardiology Montsouris, Institut Mutualiste Montsouris, Paris, France. 13Laboratory of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 14Department of Genetic Medicine and Development, Medical School, University of Geneva, Geneva, Switzerland. 15Biomedical Research Foundation of the Academy of Athens, Athens, Greece. 16Information Systems Department, University Hospitals Geneva, Geneva, Switzerland. 17Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France. 18Department of Pulmonology and Respiratory Intensive Care, French National Reference Center for Pulmonary Hypertension, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France. 19INSERM UMR_S 999, Marie Lannelongue Hospital, Le Plessis-Robinson, France. 20Gynecology and Obstetrics Department, Bicêtre Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris-Saclay University, Paris, France. 21Osiris Foundation, Geneva, Switzerland. 22Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. 23Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Received: 25 January 2022 Accepted: 26 June 2022

Published online: 19 July 2022

References

1. McLin V, Franchi-Abella S, Debray D, Korff S, Casotti V, Colledan M, et al. Congenital porto-systemic shunts in children: preliminary results from the IRCPSS. 52nd Annual Meeting ESGMHAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition) (Glasgow, Scotland, du 05/06/2019 au 08/06/2019). http://hdl.handle.net/2078.1/216438.
2. McLin V, Franchi-Abella S, Debray D, Korff S, Casotti V, Colledan M, et al. First report of the international registry of congenital porto-systemic shunts. J Pediatr Gastroenterol Nutr. 2019;68(5):678.
3. Bernard O, Franchi-Abella S, Branchereau S, Pariete D, Gauthier F, Jacqueminet E. Congenital portosystemic shunts in children: recognition, evaluation, and management. Semin Liver Dis. 2012;32(4):273–87.
4. Sokollik C, Bandsma RH, Gana JC, van den Heuvel M, Ling SC. Congenital portosystemic shunt: characterization of a multi-system disease. J Pediatr Gastroenterol Nutr. 2013;56:675–81.
5. McLin VA, Franchi Abella S, Debray D, Guérin F, Beqhetti M, Savale L, on Behalf of the Members of the International Registry of Congenital Porto-Systemic Shunts, et al. Congenital portosystemic shunts: current diagnosis and management. J Pediatr Gastroenterol Nutr. 2019;68:615–22.
6. Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital extrahepatic portosystemic shunts (Abernethy malformation): an international observational study. Hepatology. 2019;71:658–9.
7. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Hembach J, Ramsay MAE, et al. International liver transplant society practice guidelines: diagnosis, and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100(7):1440–52.
8. Sakura N, Mizoguchi N, Eguigui T, Ono H, Mawatari H, Naito K, et al. Elevated plasma bile acids in hypergalactosaemic neonates: a diagnostic clue to portosystemic shunts. Eur J Pediatr. 1997;156:716–8.
9. Guérin F, Franchi Abella S, McLin V, Ackermann O, Girard M, Cervoni JP, et al. Congenital portosystemic shunts: vascular liver diseases—position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AEEF), and ERN-rare liver. Clin Res Hepatol Gastroenterol. 2020;44(4):452–9.
10. Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Ste-Imberg C, Losay J, et al. Complications of congenitalportosystemic shunts in children: therapeutic options and out-comes. J Pediatr Gastroenterol Nutr. 2010;51:322–30.
11. Franchi-Abella S, Gonzales E, Ackermann O, Branchereau S, Pariente D, Guérin F, on behalf of the International Registry of Congenital Portosystemic Shunt. Congenital portosystemic shunts: diagnosis and treatment. Abdom Radiol. 2018;43(8):2023–36.
12. secuTrial® Web Site, a professional, GCP-compliant EDC system for collecting patient data in clinical research. https://www.secutrial.com/. Accessed 17 Sept 2021.
13. Documentation of KARNAK: a software gateway for medical image de-identification. https://osirix-foundation.github.io/karnak-documentation/. Accessed 24 Sept 2021.
14. Demonstration web site of KHEOPS platform for storage and distribution of medical images. http://www.kheops.online. Accessed 8 Sept 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.